Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737717) titled 'A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants' on July 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: ModernaTX, Inc.
Condition:
Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
Intervention:
Biological: mRNA-1469
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: July 31, 2026
Tar...